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ABSTRACT 
Objectives 
The new Transcatheter Aortic Valve Replacement (TAVR) represents a valid alternative to 
the standard surgical approach for the treatement of aortic stenosis in patients with prohibitive 
surgical risk, and at the moment, the two main access routes employed are transapical and 
transfemoral TAVR. Aim of the study is to compare the outcome of 180 consecutive patients 
who underwent transapical and transfemoral aortic valve procedures. 
Method 
From 2008 to 2014, 180 consecutive patients underwent transapical (90 patients) or 
transfemoral (90 patients) TAVR procedures at our institute. Preoperative, intraoperative and 
postoperative variables were retrospectively collected and analysed to identify risk factors for 
mortality, vascular and neurological complications. Surgical outcomes were compared. 
Results 
Mean age was 80±8.5 years and 83±8.4 years, in the TA and TF group, respectively. TA-
TAVR group presented a higher prevalence of comorbidities with more peripheral vascular 
disease, COPD, previous vascular surgery, coronary disease, previous coronary surgery and 
previous cardiac surgery.  
The logistic Euroscore I was 36±15% in the TA group and 25±14% in the TF group 
(p<0.001). 
  
Hospital mortality was similar (TA: 9%, TF: 10%, p=0.799) and early extubation seems to be 
a protective factor against hospital mortality (p=0.001). Access related vascular complications 
occurred more often in TF (TA: 3%, TF: 11%, p=0.081) whereas major or life threatening 
bleeding (TA: 3%, TF: 4%, p=1) and major stroke (TA: 2%, TF: 3%, p=1) were equally 
distributed. Postoperative acute renal failure and the need for a postoperative dialysis was 
associated with impaired neurological outcome (respectively p=0.035 and p=0.020). 
Paravalvular leaks (degree 2-4) were more prevalent in TF patients (TA: 6%, TF: 26%, 
p<0.001). 
Conclusion 
The TF and the TA TAVR groups include two different patients’ risk profiles (the TA being 
at higher risk) but mortality rate and adverse neurological outcome have a similar incidence. 
The transfemoral approach carries a higher risk of vascular complications and paravalulvar 
leaks (degree 2 or greater). 
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INTRODUCTION 
Aortic valve stenosis represents the most common acquired heart valve disease in the adult. 
The standard surgical aortic valve replacement (SAVR) remains the treatment of choice with 
proved good surgical outcome and excellent long-term results (1-4). However, elderly 
patients at high risk for surgery and suffering from severe concomitant comorbidities can 
have more benefits when new minimally invasive and riskless surgical procedures are 
employed. Moreover, because of the increasing life expectancy in western countries, we will 
face soon a greater number of patients suffering from severe aortic valve stenosis and, 
therefore, minimally invasive approaches will become even more attractive. 
Since 2007, the transcatheter aortic valve replacement (TAVR) has become a widely accepted 
alternative to standard cardiac surgery in elderly high-risk patients suffering from aortic 
stenosis and presenting a high-risk profile. In particular, two devices, the Medtronic 
CoreValve™ and the Edwards SAPIEN™ Transcatheter Heart Valve, have been already 
implanted in more than 100000 patients worldwide, with outstanding results in terms of 
hospital mortality and morbidity. 
The PARTNER trials have proven the safety and efficacy of the TAVR procedure, its 
superiority to the medical treatment and the non-inferiority to standard SAVR (5, 6). Several 
published studies have also shown good outcome, survival and hemodynamic parameters in 
early, midterm and even long-term follow-ups (7–13). 
Several alternative access routes for TAVR have been explored: the transapical, the 
transfemoral, the transaortic, the trans-subclavian and the trans-carotid. However, the two 
most popular approaches are still the transapical and the transfemoral one but the attribution 
of a patient to either a transfemoral (TF) or a transapical (TA) procedure is still debatable in 
the absence of a severe peripheral vascular disease, because of lack of randomised clinical 
trials (14–16). 
  
The aim of the present study is to assess and compare the characteristics and the clinical 
outcome of our first 90 consecutive patients treated with a transapical approach (TA-group), 
and the first 90 patients treated with a transfemoral approach (TF-group). 
 
METHODS 
We retrospectively analysed the first 90 patients who underwent TA-TAVR and the first 90 
patients who underwent TF-TAVR at our institution from November 2008 to June 2014. 
Preoperative, intraoperative and postoperative variables from the cardiovascular surgery 
database and from the clinical dossiers were prospectively collected and retrospectively 
analysed. All patients signed the informed consent for TA or TF-TAVR. 
Patients selection 
Elderly patients suffering from severe symptomatic aortic valve stenosis and carrying other 
severe comorbidities were studied for potential inclusion in the TAVR group. Then, standard 
inclusion criteria were employed to identify the good candidates and the logistic Euroscore I 
was calculated to evaluate the predicted hospital mortality. However, the final judgement 
from the in-hospital heart-team was considered essential in order to proceed with the 
transcatheter intervention, especially in case of patients not fulfilling standard criteria for 
TAVR (i.e. younger patients with severe liver disease or patients with a porcelain ascending 
aorta). In our institution the in-hospital heart-team is composed of a cardiologist, a cardiac 
surgeon (both coordinators for the TAVR program), an anaesthesiologist, a radiologist and a 
geriatrician. 
Patients enrolled in the TAVR group underwent coronary angiogram and vascular CT-scan to 
analyse alternative access routes. Patients with severe peripheral vascular disease or severe 
aortic atherosclerosis were included in the transapical TAVR group. 
A ratio of 1/3 TA-TAVR and 2/3 TF-TAVR was observed. 
  
Transapical TAVR 
Preoperative assessment for TA cases included a three-dimensional Computed Tomography 
scan (CT-scan), a coronary angiogram and a trans-thoracic echocardiogram. Transapical 
TAVR was performed under general anesthesia through a left antero-lateral mini-thoracotomy 
at fifth intercostal space. Intraoperative cardiac imaging included trans-esophageal 
echocardiogram and fluoroscopy. The apex was always prepared with two reinforced 
concentric purse-string sutures (Polipropylene 3-0 or 2-0 sutures with pledgets) and the 
devices were the balloon-expandable Edwards Sapien™ (2008-2010), Edwards Sapien™ XT 
(2010-2014) and Edwards Sapien™ 3 (2014) transcatheter heart valves (THV) (Edwards 
Lifesceinces, Irvine, CA, US). 
In the very beginning of our series, even non-complicated patients were transferred intubated 
in the intensive care unit while, after the preliminary experience, patients were rapidly 
extubated in the cath lab and then transferred to the intermediate care unit. 
Transfemoral TAVR 
Patients at high surgical risk with good peripheral vascular access underwent transfemoral 
procedures under general anesthesia. In our institution, the transfemoral access is performed 
through a 3cm skin incision at the groin in order to punction the femoral artery under direct 
vision and prevent vascular damages. Preoperative and intraoperative assessment and imaging 
were the same as TA-TAVR while the employed devices were the balloon-expandable 
Sapien™, Sapien XT™ and Sapien™ 3 (2014) THV from Edwards Lifesciences and the self-
expandable CoreValve™ (Medtronic corporation, Minneapolis, MN, USA). All non-
complicated patients were rapidly extubated in the cath lab and transferred to the intermediate 
care unit. 
Statistical analysis 
  
The statistical analysis was performed using R (version 3.2.2). Continuous variables are 
summarized as mean ± Standard Deviation (SD) and a t-test is used to compare the two 
groups (TA and TF). Categorical variables are presented as numbers and proportions (%) and 
a χ2 test or a Fisher exact test is used to compare the two groups. Selected categorical and 
continuous preoperative and postoperative variables were analyzed as risk factors for hospital 
mortality (defined as any death occurring within 30 days or during the same hospital 
admission) or neurological and vascular complications, using univariate logistic regression. A 
p-value below 0.05 was considered statistically significant. Authors had full access to data 
and they take responsibility for their integrity. 
 
RESULTS 
From November 2008 to June 2014, 90 patients underwent TA-TAVR and 90 patients TF-
TAVR at our institution. Baseline characteristics and preoperative assessment data are 
described in Table 1 and Table 2.  
Mean age was different in the 2 groups (mean age of 80 ± 8.5 years and 83 ± 8.4 years, in the 
TA and TF group, respectively; p=0.014), while the sex distribution was similar (50% male 
patients in the TA group and 41% in the TF group, p=0.231). The TA-TAVR group presented 
a higher prevalence of concomitant comorbidities: more peripheral vascular disease in the TA 
group (TA: 79%, TF: 22%, p<0.001), more COPD in the transapical group (TA: 32%, TF: 
10%, p<0.001), higher prevalence of previous vascular surgery (TA: 14%, TF: 4%, p=0.039), 
coronary disease (TA: 60%, TF: 40%, p=0.007), previous coronary surgery (TA: 21%, TF: 
9%, p=0.022) and previous cardiac surgery (TA: 28%, TF: 17%, p=0.073) in the TA group. 
  
Also, 13% of patients in the TA group had a porcelain aorta, versus none in the TF group 
according to the fact that this condition was a criteria of assignation to the TA-TAVR group. 
More patients with a critical preoperative state were included in the TA group (TA: 14%, TF: 
2%, p=0.005), and the calculated logistic Euroscore was higher in the TA group (36 ± 15 % 
for the TA group compared to 25 ± 14 % for the TF group; p<0.001). The mean left ventricle 
ejection fraction (LVEF) was better in the TF group, with a LVEF>50% in the 66% of TF 
patients and 47% of TA patients (p=0.008). 
To what may concern the intraoperative data, the successful implantation rate was 100% and 
the mean procedural time was longer in the TF group (TA: 98 ± 33 minutes, TF: 127 ± 56 
minutes, p<0.001). Eleven patients were redo valve-in-valve procedures for degenerated 
aortic bioprosthesis, while seven patients received two transcatheter heart valves because of 
malpositioning or migration of the first one. 
Mean valve size and size distribution are listed in Table 3. 
With regards to the mortality and hospital outcome, variables were collected following VARC 
criteria and are listed in Table 4 (see Figure 1). Hospital mortality for the two groups was 
similar (TA: 9%, TF: 10%, p=0.799) with a learning curve effect in the beginning of our 
experience (Figure 2). The main cause of death in the TA group was respiratory failure 
(37%), whereas in the TF group was the major stroke (33%). Major vascular complications 
(access related) occurred more often in the TF group (TA: 3%, TF: 11%, p=0.081) whereas 
major or life threatening bleeding (TA: 3%, TF: 4%, p=1), major stroke (TA: 2%, TF: 3%, 
p=1), and bailout Sapien-in-Sapien procedures (TA: 3%, TF: 4%, p=1) were equally 
distributed. 
Re-thoracotomy for bleeding was performed in three TA patients and a percutaneous 
pericardial drainage for tamponade was urgently performed in two TF patients. Patients 
requiring postoperative dialysis were 3 in the TA group and none in the TF. 
  
With regards to the onset of new conduction abnormalities leading to pacemaker 
implantation, there were five implanted devices in the TF group and two in the TA group 
(p=0.444). 
Postoperative echocardiographic controls showed similar mean transaortic peak (TA: 17 ± 9.4 
mmHg, TF: 18 ± 9.5, mmHg; p=0.219) and mean gradients (TA: 9.2 ± 5.1 mmHg, TF: 9.7 ± 
5.5 mmHg; p=0.563). Paravalvular leaks degree 2 to 4 were detected more often in TF 
patients (TA: 6%, TF: 26%, p<0.001) with 20 grade 2 paravalvular leaks in the TF group and 
5 in the TA group, two grade 3 in the TF group and none in the TA group, and only 1 
paravalvular leak grade 4 in the TF population. 
Selected variables were analyzed as potential risk factors for hospital mortality, major 
vascular complications and neurological complications (Table 5). 
Concerning the hospital mortality, several variables were statistically related to a higher risk 
of procedural and hospital death, these variables were: a critical preoperative state (p=0.026; 
OR, 4.25; 95% CI, 1.19-15.24), the occurrence of complications (p<0.001; OR, 33.25; 95% 
CI, 7.22-153), of major vascular complications (p=0.001; OR, 8.07; 95% CI, 2.28-28.53), of 
valve migration (p=0.014; OR, 21.6; 95% CI, 1.85-252), of life-threatening bleeding 
(p=0.001; OR, 16.41; 95% CI, 3.31-81.29), of postoperative stroke (p=0.003; OR, 17.25; 95% 
CI, 2.66-112), of postoperative acute renal failure (p=0.022; OR, 10.73; 95% CI, 1.41-81.73), 
of postoperative dialysis (p=0.014; OR, 21.6; 95% CI, 1.85-252) and the need for a 
cardiopulmonary bypass (p=0.003; OR, 34.71; 95% CI, 3.38-356). Whereas the early 
extubation represents a protective factor against hospital mortality (p=0.001; OR, 0.16; 95% 
CI, 0.05-0.48). 
About risk factors for major vascular complications, the cardiopulmonary bypass use seems to 
be associated with higher rate of severe vascular complications (p=0.010; OR, 15; 95% CI, 
1.93-116). Concerning the risk factors for stroke, the onset of postoperative acute renal failure 
  
and the use of a postoperative dialysis were associated with a poor neurological outcome 
(p=0.035; OR, 14.33; 95% CI, 1.21-169; and p=0.020; OR, 21.62; 95% CI, 1.61-290, 
respectively). 
  
DISCUSSION 
Major findings of our study are that, despite the transfemoral and the transapical groups 
represent two different populations with two different risk profiles, the hospital mortality rate 
is similar, whereas the presence of postoperative paravalvular leaks degree 2 to 4 and major 
access related vascular complications occurred more often in the TF group. 
Our study compared the outcomes of 180 consecutive patients included in a transapical and a 
transfemoral transcatheter aortic valve implantation group and registry (hospital database). 
Patients in the transapical group had a higher prevalence of comorbidities, a higher calculated 
logistic Euroscore and were more often in a preoperative critical state. Therefore, according to 
the fact that patients with severe peripheral vascular disease or severe aortic atherosclerosis 
were included in the transapical group, we had to deal with two patient populations carrying 
two different risk profiles. 
However, the mortality rate and the neurological outcome are similar despite a longer 
intensive care unit length of stay and extubation time for the TA group. This is due to the fact 
that at the very beginning of our TAVI experience the transapical TAVI patients were all 
transferred, intubated, to the intensive care unit and extubated after few hours. 
On the other hand, the transfemoral TAVI began few years later and the majority of the 
uncomplicated cases were rapidly extubated in the CathLab and transferred to an intermediate 
care unit. 
  
To what may concern the mortality rate in previously reported cohorts of patients, several 
cohorts report lower mortality rates. In a prospective study with a cohort of 1000 patients, 
Schymik and al. reported mortality rates of 6.5 % for the TF group and 6.1 % for the TA 
group (18). In a single-center experience in the US with a retrospective design, Murarka and 
al. observed mortality rates of 4.5 % for the TF group and 5.3 % for the TA group (17). In 
another retrospective cohort study, Van der Boon and al. reported mortality rates of 6.4 % for 
the TF group and 15.7 % for the TA group (15). But none of these 3 aforementioned studies 
were able to demonstrate a statistically significant difference between the two approaches and 
this is in line with our findings.  
The neurological outcome in our series shows similar results for the TA and the TF approach 
and we didn’t observe a significant difference. Our results are in line with data presented in 
literature. For instance, in the study of Schymik et al. with the prospective cohort of 1000 
patients, there was a 2.3 % of stroke rate in the TF group and 1.7 % in the TA group with a 
non-significant p-value (18). Other studies reported similar conclusions (14, 15, 17).  
Concerning the paravalvular leak after TAVI, we have seen a great improvement after the 
introduction of the new Sapien 3 THV that provides better valve coaptation to the native 
aortic annulus. The paravalvular leak degree 2 to 4 was observed more often in TF cases and 
this finding is in line with a retrospective study from Greason and al., who reported 12 % of 
moderate and severe paravalvular leaks in the TF group versus 8.4 % in the TA group. 
However, other TAVI series didn’t show this trend. In a retrospective study from Murarka 
and al. quite similar results between the two groups were observed, with an incidence of 7.6 
% in the TF group versus 7 % in the TA group and a p-value of 0.999. 
  
Last but not least, the incidence of major vascular complications in our series seems to be 
higher in the TF group but the result is not statistically significant. If we take into 
consideration recently published cohorts of TAVI patients, we can see that the incidence of 
this complication is much more prevalent in the TF subgroup. Schymik and al. reported 17.5 
% of major vascular complications in the TF group versus 2.5 % in the TA group with a p-
value of <0.0001 (18). In their retrospective study, Murarka and al. observed a similar trend, 
with 12.1 % of major vascular complications in the TF group versus 0 % in the TA group, 
also with a highly significant p-value (17). 
An important point of discussion is the technical development of our TAVI devices: the new 
generations of stent-valve equipments have more performant valve designs and low-profile 
delivery systems that assure a lower incidence of paravalvulare leak, a lower risk of vascular 
damages and a more friendly and easy-to-use valve sizing and deployment during the 
procedure. This development can have a great impact in the mortality and morbidity rate 
during TAVI procedures allowing for the use of such transcatheter devices in mid-risk profile 
patients and younger patients with aortic valve stenosis. 
 
LIMIT OF THE STUDY 
Our study is a retrospective, single centre experience with a relatively small number of 
enrolled patients. Moreover, this patient population represents the preliminary experience in 
TAVI procedures of our centre and, therefore, a physiologic learning curve can have 
negatively affected the clinical outcome. 
 
 
 
 
  
CONCLUSION 
This study shows our preliminary experience in TA and TF TAVI in elderly high-risk patients 
and the results are in line with recently published data. Based on our findings, we can confirm 
that there is a trend towards a lowering mortality and morbidity rate in the TAVI patient 
population mostly due to both the improved surgeons’ and cardiologists’ transcatheter skills 
for TAVI and the advent of new less traumatic and easy-to-use second-generation TAVI 
devices. Nevertheless, further clinical studies are necessary to corroborate our findings and to 
confirm the long-term durability of stent-valves. 
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TABLES 
 
Table 1. Demographics, symptoms, and risk factors. 
 
Overall 
(N=180) 
TA-TAVR 
(N=90) 
TF-TAVR 
(N=90) 
p 
No. of patients 180 90 90  
Age (years) 
82 ± 8.6 
(range 45-95, 
median 84) 
80 ± 8.5 
(range 54-95, 
median 81) 
83 ± 8.4 
(range 45-94, 
median 85) 
0.014 
Men 82 (46%) 45 (50%) 37 (41%) 0.231* 
COPD 38 (21%) 29 (32%) 9 (10%) < 0.001* 
Peripheral vascular 
disease 
91 (51%) 71 (79%) 20 (22%) < 0.001* 
Previous vascular 
surgery 
17 (9%) 13 (14%) 4 (4%) 0.039 
Coronary disease 90 (50%) 54 (60%) 36 (40%) 0.007* 
Previous coronary 
surgery 
27 (15%) 19 (21%) 8 (9%) 0.022* 
Previous cardiac surgery 40 (22%) 25 (28%) 15 (17%) 0.073* 
Previous coronary 
angioplasty/stenting 
28 (16%) 13 (14%) 15 (17%) 0.681* 
Systemic hypertension 117 (65%) 56 (62%) 61 (68%) 0.435* 
Chronic renal 
insufficiency 
75 (42%) 38 (42%) 37 (41%) 0.880* 
Dialysis 7 (4%) 4 (4%) 3 (3%) 1 
  
Previous stroke 20 (11%) 11 (12%) 9 (10%) 0.635* 
Diabetes (under insulin 
treatment) 
30 (17%) 18 (20%) 12 (13%) 0.230* 
Liver disease (CHILD A, 
B, C) 
5 (3%) 3 (3%) 2 (2%) 1 
Previous PM 
implantation 
21 (12%) 9 (10%) 12 (13%) 0.486* 
Chest X-Ray therapy for 
cancer 
16 (9%) 7 (8%) 9 (10%) 0.600* 
Critical preoperative 
state 
15 (8%) 13 (14%) 2 (2%) 0.005 
Porcelain aorta 12 (13%) 12 (13%) 0 (0%) 1 
Mean logistic Euroscore 
I (%) 
31 ± 16 36 ± 15 25 ± 14 < 0.001 
Data are presented as mean ± SD or N (%). 
* Chi2 value, otherwise it’s a Fischer test or a T-Test value 
COPD = Chronic Obstructive Pulmonary Disease; PM = pacemaker. 
 
 
  
  
Table 2. Preoperative CT-scan assessment and aortic valve hemodynamic. 
 
Overall 
(N=180) 
TA-TAVR 
group 
 (N=90) 
TF-TAVR 
group 
 (N=90) 
p 
Transaortic peak gradient (mmHg) 67 ± 26 62 ± 25 71 ± 28  
Mean aortic valve area (cm²) 0.9 ± 3.4 1.2 ± 4.8 0.7 ± 0.2  
Indexed mean aortic valve area 
(cm²/m²) 
0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1  
Mean left ventricle ejection 
fraction (%) 
54 ± 13 52 ± 12 56 ± 13  
                >50% 101 (56%) 42 (47%) 59 (66%) 0.008* 
             30 – 50% 70 (39%) 42 (47%) 28 (32%)  
                <30% 8 (4%) 6 (6%) 2 (2%)  
Pulmonary hypertension 101 (56%) 48 (53%) 53 (59%) 0.453* 
Mean aortic annulus diameter at 
CT-scan (mm) 
23 ± 2.3 23 ± 2.5 24 ± 2.1  
Mean aortic annulus diameter at 
TEE (mm) 
23 ± 2.2 22 ± 2 22 ± 2.4  
Mean distance between aortic 
annulus and LCA (mm) 
13 ± 2.9 12 ± 2 14 ± 3.2  
Mean distance between aortic 
annulus and RCA (mm) 
134 ± 4 12 ± 3 15 ± 4.4  
Data are presented as mean ± SD or N (%). 
* Chi2 value 
  
CT = Computed Tomography; TEE = Trans-Esophageal Echocardiography; LCA = Left 
Coronary Artery; RCA = Right Coronary Artery. 
 
Table 3.  Intraoperative data. 
 Overall 
(N=180) 
TA-TAVR 
group 
 (N=90) 
TF-TAVR 
group 
 (N=90) 
p 
Sapien™ and Sapien XT™ 
THV 
146 (81%) 86 (96%) 60 (67%)  
Sapien 3™ 8 (4%) 4 (4%) 4 (4%)  
CoreValve™ 26 (29%) 0 (0%) 26 (29%)  
Valve-in-valve (in degenerated 
bioprosthesis) 
12 (7%) 7 (8%) 5 (6%) 0.550* 
Bailout valve-in-valve 7 (4%) 3 (3%) 4 (4%) 1 
Mean valve size (mm) 25 ± 2.1 25 ± 1.9 25.3 ± 2.2  
Size distribution:     
23 mm 75 (42%) 40 (44%) 35 (39%)  
26 mm 77 (43%) 43 (48%) 44 (49%)  
29 mm 14 (8%) 7 (8%) 7 (8%)  
31 mm 4 (4%) 0 (0%) 4 (4%)  
Mean procedural time (min) 113 ± 48 98 ± 33 127 ± 56 < 0.001 
Data are presented as mean ± SD or N (%). 
* Chi2 value, otherwise it’s a Fischer test or a T-Test value 
THV = Transcatheter Heart Valve 
 
  
Table 4. Postoperative clinical results. 
 Overall 
(N=180) 
TA-TAVR 
group 
 (N=90) 
TF-TAVR 
group 
 (N=90) 
p 
Hospital mortality 17 (9%) 8 (9%) 9 (10%) 0.799* 
Cause of death     
Respiratory failure 3 (2%) 3 (3%) 0 (0%)  
Cardiac tamponade for aortic 
annulus rupture 
2 (1%) 0 (0%) 2 (2%)  
Valve migration 1 (1%) 0 (0%) 1 (1%)  
Myocardial infarction 1 (1%) 1 (1%) 0 (0%)  
Cardiac failure 1 (1%) 0 (0%) 1 (1%)  
Sudden death 1 (1%) 1 (1%) 0 (0%)  
Cardiac arrest 2 (1%) 0 (0%) 2 (2%)  
Life threatening bleeding 1 (1%) 1 (1%) 0 (0%)  
Multiple organ failure 1 (1%) 1 (1%) 0 (0%)  
Major stroke 4 (2%) 1 (1%) 3 (3%)  
Complicated procedures 48 (27%) 21 (23%) 23 (26%) 0.729* 
Kind of complication     
Major vascular complication 
(access related) 
13 (7%) 3 (3%) 10 (11%) 0.081 
Valve migration 3 (2%) 1 (1%) 2 (2%) 1 
Major or life-threatening 
bleeding 
7 (4%) 3 (3%) 4 (4%) 1 
Major stroke 5 (3%) 2 (2%) 3 (3%) 1 
  
Coronary occlusion 1 (1%) 1 (1%) 0 (0%) 1 
Bailout Sapien-in-Sapien 7 (4%) 3 (3%) 4 (4%) 1 
Pneumonia 6 (3%) 5 (6%) 1 (1%) 0.211 
Rethoracotomy for bleeding or 
pericardial drainage for 
tamponade  
5 (3%) 3 (3%) 2 (2%) 1 
Postoperative acute renal 
failure 
4 (2%) 3 (3%) 1 (1%) 0.621 
Transitory dialysis 3 (2%) 3 (3%) 0 (0%) 0.246 
PM implantation for onset of 
new conduction abnormality 
7 (4%) 2 (2%) 5 (6%) 0.444 
Conversion to full sternotomy 2 (1%) 2 (2%) 0 (0%) 0.497 
Bailout CPB use 4 (2%) 4 (4%) 0 (0%) 0.121 
Extubation in OR or Cath lab 123 (68%) 40 (44%) 83 (92%) < 0.001* 
Mean ICU stay (days) 
1.4 ± 4.1 
(median: 0) 
2.6 ± 5.5 
(median: 1) 
0.2 ± 0.7 
(median: 0) 
< 0.001 
Mean hospital stay (days) 
11.7 ± 9.1 
(median: 9) 
13.9 ± 9.5 
(median: 10) 
9.4 ± 8.2 
(median: 8) 
< 0.001 
Mean transaortic peak gradient 
(mmHg) 
17.6 ± 9.5 16.7 ± 9.4 18.5 ± 9.5 0.219 
Mean transaortic mean 
gradient (mmHg) 
9.5 ± 5.3 9.2 ± 5.1 9.7 ± 5.5 0.563 
Paravalvular leak = 0 101 (56%) 70 (78%) 31 (34%)  
Paravalvular leak 2-4 28 (16%) 5 (6%) 23 (26%) < 0.001* 
Paravalvular leak = 1 48 (27%) 15 (17%) 33 (37%)  
  
Paravalvular leak = 2 25 (14%) 5 (5%) 20 (22%)  
Paravalvular leak = 3 2 (1%) 0 (0%) 2 (2%)  
Paravalvular leak = 4 1 (1%) 0 (0%) 1 (1%)  
Data are presented as mean ± SD or N (%). 
* Chi2 value, otherwise it’s a Fischer test or a T-Test value 
CPB = Cardio-pulmonary Bypass; OR = Operating Room; ICU = Intensive Care Unit 
  
  
Figure 1.  Distribution of complications following the VARC criteria.
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Figure 2. Time evolution of hospital mortality. 
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Table 5. Logistical regression analysis (N:180). 
Hospital mortality – Univariate logistical regression analysis 
Total 
n.0 n.1 
 
163 17 
 Binary variables n.0 p.0 n.1 p.1 or or.sd or.ci95 p 
Transfemoral 
procedure 81 49,7% 9 52,9% 1,14 1,67 0,42 3,10 0,799 
Gender (M) 76 46,6% 6 35,3% 0,62 1,70 0,22 1,77 0,375 
COPD 34 20,9% 4 23,5% 1,17 1,83 0,36 3,81 0,798 
Vascular disease 81 49,7% 10 58,8% 1,45 1,68 0,52 3,98 0,476 
Previous vascular 
surgery 16 9,8% 1 5,9% 0,57 2,90 0,07 4,62 0,602 
Coronary disease 82 50,3% 8 47,1% 0,88 1,67 0,32 2,39 0,799 
Previous CABG 25 15,3% 2 11,8% 0,74 2,19 0,16 3,42 0,696 
Previous cardiac 
surgery 35 21,5% 5 29,4% 1,52 1,76 0,50 4,62 0,456 
Previous STENT 23 14,1% 5 29,4% 2,54 1,78 0,82 7,87 0,107 
HTA 108 66,3% 9 52,9% 0,57 1,67 0,21 1,57 0,278 
Renal insufficiency 66 40,5% 9 52,9% 1,65 1,67 0,61 4,51 0,326 
Dialysis 7 4,3% 0 0,0% 
     Stroke 17 10,4% 3 17,6% 1,84 1,99 0,48 7,06 0,374 
Diabetes 27 16,6% 3 17,6% 1,08 1,95 0,29 4,01 0,909 
Liver disease 5 3,1% 0 0,0% 
     PM implantation 19 11,7% 2 11,8% 1,01 2,21 0,21 4,77 0,989 
  
Thorax Xray therapy 14 8,6% 2 11,8% 1,42 2,23 0,29 6,85 0,663 
Critical state 11 6,7% 4 23,5% 4,25 1,92 1,19 15,24 0,026 
Porcelain aorta 12 14,6% 0 0,0% 
     EuroScore>20% 117 71,8% 12 70,6% 0,94 1,75 0,31 2,83 0,917 
LVEF>50% 91 55,8% 10 62,5% 1,32 1,72 0,46 3,80 0,608 
Pulmonary 
hypertension 95 58,3% 6 35,3% 0,39 1,70 0,14 1,11 0,077 
Valve in valve 11 6,7% 1 5,9% 0,86 2,94 0,10 7,13 0,892 
Complications 30 18,4% 15 88,2% 33,25 2,18 7,22 153 0,000 
Major vascular 
complication 8 4,9% 5 29,4% 8,07 1,90 2,28 28,53 0,001 
Valve migration 1 0,6% 2 11,8% 21,60 3,50 1,85 252 0,014 
Lifethreatening 
bleeding 3 1,8% 4 23,5% 16,41 2,26 3,31 81,29 0,001 
Postoperative stroke 2 1,2% 3 17,6% 17,25 2,60 2,66 112 0,003 
Coronary occlusion 0 0,0% 1 5,9% 
     Bailout Sapien in 
Sapien 7 4,3% 0 0,0% 
     Pneumonia 4 2,5% 2 11,8% 5,30 2,48 0,90 31,37 0,066 
Pericardial drainage or 
rethoracotomy for 
bleeding 5 3,1% 0 0,0% 
     Postoperative ARF 2 1,2% 2 11,8% 10,73 2,82 1,41 81,73 0,022 
Postoperative dialysis 1 0,6% 2 11,8% 21,60 3,50 1,85 252 0,014 
PM implantation post 6 3,7% 1 5,9% 1,64 3,04 0,19 14,45 0,658 
  
TAVI 
Conversion to 
sternotomy 0 0,0% 2 11,8% 
     CPB 1 0,6% 3 17,6% 34,71 3,28 3,38 356 0,003 
Extubation in OR or 
CathLab 118 72,4% 5 29,4% 0,16 1,75 0,05 0,48 0,001 
Paravalvular leak 
(degree 2-4) 25 15,4% 3 20,0% 1,37 1,98 0,36 5,21 0,644 
OR = odds ratio; OR.SD = odds ratio standard deviation; OR.CI95 = odds ratio 95% 
confidence interval; p = p value; COPD = chronic obstructive pulmonary disease; CABG = 
coronary artery bypass graft; PM = pacemaker; LVEF = left ventricular ejection fraction; 
ARF = acute renal failure; CPB = Cardio-pulmonary Bypass 
 
Major vascular complications - Univariate logistical regression analysis 
 
 
n.0 n.1 
 Total 167 13 
 
 Binary variables n.0 p.0 n.1 p.1 or or.sd or.ci95 p 
Way (TF) 80 47,9% 10 76,9% 3,62 1,97 0,96 13,64 0,057 
Gender (M) 78 46,7% 4 30,8% 0,51 1,86 0,15 1,71 0,274 
COPD 36 21,6% 2 15,4% 0,66 2,21 0,14 3,12 0,602 
Vascular disease 84 50,3% 7 53,8% 1,15 1,78 0,37 3,58 0,806 
Previous vascular 
surgery 15 9,0% 2 15,4% 1,84 2,26 0,37 9,10 0,453 
  
Coronary disease 85 50,9% 5 38,5% 0,60 1,81 0,19 1,92 0,392 
Previous CABG 26 15,6% 1 7,7% 0,45 2,89 0,06 3,62 0,455 
Previous cardiac 
surgery 38 22,8% 2 15,4% 0,62 2,20 0,13 2,91 0,542 
Previous coronary 
stenting 28 16,8% 0 0,0% 
     HTA 110 65,9% 7 53,8% 0,60 1,79 0,19 1,88 0,385 
Renal insufficiency 72 43,1% 3 23,1% 0,40 1,97 0,11 1,49 0,171 
Dialysis 7 4,2% 0 0,0% 
     Stroke 20 12,0% 0 0,0% 
     Diabetes 29 17,4% 1 7,7% 0,40 2,89 0,05 3,17 0,383 
Liver disease 5 3,0% 0 0,0% 
     PM implantation 20 12,0% 1 7,7% 0,61 2,91 0,08 4,97 0,646 
Thorax Xray therapy 14 8,4% 2 15,4% 1,99 2,27 0,40 9,87 0,401 
Critical state 14 8,4% 1 7,7% 0,91 2,94 0,11 7,53 0,931 
Porcelain aorta 12 13,8% 0 0,0% 
     EuroScore>20% 121 72,5% 8 61,5% 0,61 1,81 0,19 1,96 0,404 
LVEF>50% 95 57,2% 6 46,2% 0,64 1,78 0,21 1,99 0,441 
Pulmonary 
hypertension 96 57,5% 5 38,5% 0,46 1,81 0,15 1,47 0,192 
Valve in valve 11 6,6% 1 7,7% 1,18 2,96 0,14 9,94 0,878 
Complications 32 19,2% 13 100% 
     Hospital mortality 12 7,2% 5 38,5% 8,07 1,90 2,28 28,53 0,001 
Valve migration 3 1,8% 0 0,0% 
     
  
Lifethreatening 
bleeding 0 0,0% 7 53,8% 
     Postoperative stroke 4 2,4% 1 7,7% 3,40 3,18 0,35 32,82 0,291 
Coronary occlusion 1 0,6% 0 0,0% 
     Bailout Sapien in 
Sapien 7 4,2% 0 0,0% 
     Pneumonia 6 3,6% 0 0,0% 
     Pericardial drainage or 
rethoracotomy for 
bleeding 4 2,4% 1 7,7% 3,40 3,18 0,35 32,82 0,291 
Postoperative ARF 3 1,8% 1 7,7% 4,56 3,30 0,44 47,19 0,204 
Postoperative dialysis 2 1,2% 1 7,7% 6,87 3,53 0,58 81,36 0,126 
PM implantation post 
TAVI 7 4,2% 0 0,0% 
     Conversion to 
sternotomy 1 0,6% 1 7,7% 13,83 4,24 0,81 235 0,069 
CPB 2 1,2% 2 15,4% 15,00 2,85 1,93 116 0,010 
Extubation in OR or 
CathLab 117 70,1% 6 46,2% 0,37 1,79 0,12 1,14 0,084 
Paravalvular leak 
(degree 2-4) 26 15,8% 2 16,7% 1,07 2,23 0,22 5,16 0,934 
OR = odds ratio; OR.SD = odds ratio standard deviation; OR.CI95 = odds ratio 95% 
confidence interval; p = p value; COPD = chronic obstructive pulmonary disease; CABG = 
coronary artery bypass graft; PM = pacemaker; LVEF = left ventricular ejection fraction; 
ARF = acute renal failure; CPB = Cardio-pulmonary Bypass 
  
 
Postoperative Stroke - Univariate logistical regression analysis 
 
n.0 n.1 
 
Total 175 5 
 Binary variables n.0 p.0 n.1 p.1 or or.sd or.ci95 p 
Way (TF) 87 49,7% 3 60,0% 1,52 2,52 0,25 9,30 0,652 
Gender (M) 81 46,3% 1 20,0% 0,29 3,09 0,03 2,65 0,273 
COPD 37 21,1% 1 20,0% 0,93 3,11 0,10 8,59 0,951 
Vascular disease 88 50,3% 3 60,0% 1,48 2,52 0,24 9,09 0,670 
Previous vascular 
surgery 17 9,7% 0 0,0%      
Coronary disease 88 50,3% 2 40,0% 0,66 2,52 0,11 4,04 0,652 
Previous CABG 26 14,9% 1 20,0% 1,43 3,12 0,15 13,33 0,752 
Previous cardiac 
surgery 38 21,7% 2 40,0% 2,40 2,54 0,39 14,91 0,346 
Previous coronary 
stenting 27 15,4% 1 20,0% 1,37 3,12 0,15 12,74 0,782 
HTA 114 65,1% 3 60,0% 0,80 2,53 0,13 4,93 0,812 
Renal insufficiency 75 42,9% 0 0,0% 
     Dialysis 7 4,0% 0 0,0% 
     Stroke 19 10,9% 1 20,0% 2,05 3,14 0,22 19,33 0,530 
Diabetes 29 16,6% 1 20,0% 1,26 3,12 0,14 11,67 0,840 
Liver disease 5 2,9% 0 0,0% 
     PM implantation 21 12,0% 0 0,0% 
     
  
Thorax Xray therapy 16 9,1% 0 0,0% 
     Critical state 15 8,6% 0 0,0% 
     Porcelain aorta 12 13,6% 0 0,0% 
     EuroScore>20% 124 70,9% 5 100% 
     LVEF>50% 97 55,7% 4 80,0% 3,18 3,09 0,35 28,99 0,306 
Pulmonary 
hypertension 98 56,0% 3 60,0% 1,18 2,52 0,19 7,23 0,859 
Valve in valve 12 6,9% 0 0,0% 
     Complications 40 22,9% 5 100% 
     Hospital mortality 14 8,0% 3 60,0% 17,25 2,60 2,66 112 0,003 
Major vascular 
complication 12 6,9% 1 20,0% 3,40 3,18 0,35 32,82 0,291 
Valve migration 3 1,7% 0 0,0% 
     Lifethreatening 
bleeding 7 4,0% 0 0,0% 
     Coronary occlusion 1 0,6% 0 0,0% 
     Bailout Sapien in 
Sapien 7 4,0% 0 0,0% 
     Pneumonia 6 3,4% 0 0,0% 
     Pericardial drainage 
or rethoracotomy for 
bleeding 5 2,9% 0 0,0% 
     Postoperative ARF 3 1,7% 1 20,0% 14,33 3,53 1,21 169 0,035 
Postoperative dialysis 2 1,1% 1 20,0% 21,62 3,76 1,61 290 0,020 
PM implantation post 7 4,0% 0 0,0% 
     
  
TAVI 
Conversion to 
sternotomy 2 1,1% 0 0,0% 
     CPB 4 2,3% 0 0,0% 
     Extubation in OR or 
CathLab 121 69,1% 2 40,0% 0,30 2,53 0,05 1,83 0,191 
Paravalvular leak 
(grade 2-4) 28 16,3% 0 0,0% 
     OR = odds ratio; OR.SD = odds ratio standard deviation; OR.CI95 = odds ratio 95% 
confidence interval; p = p value; COPD = chronic obstructive pulmonary disease; CABG = 
coronary artery bypass graft; PM = pacemaker; LVEF = left ventricular ejection fraction; 
ARF = acute renal failure; CPB = Cardio-pulmonary Bypass 
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